Dr. Mirtsching studies treatments for advanced cancers, especially breast and colorectal cancers. He investigates how specific therapies, such as nanoparticle albumin-bound paclitaxel and cetuximab, can aid patients who have limited options available after other treatments fail. Additionally, he explores ways to help patients manage side effects like anemia that result from chemotherapy, utilizing drugs like darbepoetin alfa to improve hemoglobin levels and reduce fatigue.
Key findings
In a study on nanoparticle albumin-bound paclitaxel, 42% of patients responded positively, increasing to 52% for those with HER2-positive tumors, and 69% overall benefited from the treatment.
In the comparison of darbepoetin alfa dosing schedules, 76% of patients on a weekly schedule reached target hemoglobin levels, compared to 71% on a less frequent schedule, demonstrating similar effectiveness with fewer clinic visits.
The study of pegfilgrastim found only 2.9% of patients experienced hospitalization due to low white blood cell counts during the first treatment cycle, increasing to 5.6% over multiple cycles, highlighting its role in reducing complications.
Cetuximab led to a 12.4% response rate in patients with advanced colorectal cancer, with an average survival time of 6.6 months.
Darbepoetin alfa helped 84% of patients with chemotherapy-induced anemia report significant improvements in their hemoglobin levels, with fatigue scores improving by about 27%.
Frequently asked questions
Does Dr. Mirtsching study breast cancer?
Yes, Dr. Mirtsching studies treatments for metastatic breast cancer, especially those targeting HER2-positive tumors.
What treatments has Dr. Mirtsching researched?
He has researched treatments like nanoparticle albumin-bound paclitaxel, cetuximab, and darbepoetin alfa for anemia related to chemotherapy.
Is Dr. Mirtsching's work relevant to chemotherapy patients?
Yes, his work focuses on managing side effects of chemotherapy and improving treatment effectiveness for cancer patients.
What are the effects of the drugs he studies?
Dr. Mirtsching's studies have shown significant positive effects, such as increased hemoglobin levels and reduced chemotherapy-related complications.
How does Dr. Mirtsching help patients with colon cancer?
He researches targeted therapies like cetuximab to improve outcomes for patients with advanced colorectal cancer who have not responded to other treatments.
Publications in plain English
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
2011
Clinical breast cancer
Mirtsching B, Cosgriff T, Harker G, Keaton M, Chidiac T +1 more
Plain English This study examined the effects of a treatment called nanoparticle albumin-bound paclitaxel, given weekly, for patients with advanced breast cancer, especially those with an overexpression of a protein known as HER2. They found that 42% of all patients responded positively to the treatment, and this response rate increased to 52% for those with HER2-positive tumors. The treatment was also well tolerated, with a good safety profile, leading to an overall benefit in 69% of patients.
Who this helps: Patients with metastatic breast cancer, especially those with HER2-positive tumors.
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
2010
BMC cancer
Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P +3 more
Plain English This study looked at two different ways to give a drug called darbepoetin alfa to treat anemia caused by chemotherapy. It compared giving the drug weekly to giving it every 2 or 3 weeks over 25 weeks. The results showed that 71% of patients on the extended dosage every two or three weeks and 76% on the weekly schedule reached the target hemoglobin level, with only a tiny difference in hemoglobin change between the groups, indicating that the extended schedule is just as effective as weekly dosing.
Who this helps: This helps patients undergoing chemotherapy by potentially reducing the number of clinic visits needed for treatment.
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
2007
The oncologist
Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ +2 more
Plain English This study looked at the effects of pegfilgrastim, a medication that helps boost white blood cell production, in patients receiving chemotherapy for various cancers. Researchers found that only 2.9% of patients had to be hospitalized due to low white blood cell counts (neutropenia) during their first cycle of treatment, and this increased to 5.6% over multiple cycles. These findings are important because they show that pegfilgrastim can significantly reduce complications from chemo-related neutropenia, allowing patients to stay healthier and continue their treatment on schedule.
Who this helps: This helps cancer patients undergoing chemotherapy.
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
2006
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P +8 more
Plain English This study looked at the effectiveness of cetuximab, a targeted cancer therapy, in patients with advanced colorectal cancer that had not responded to standard treatments. Out of 346 patients treated, about 12.4% showed a positive response to the drug, with an average survival time of 6.6 months. Additionally, most patients experienced a severe rash, which seemed to be linked to better treatment outcomes.
Who this helps: This information benefits doctors and patients with advanced colorectal cancer who have run out of standard treatment options.
Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
2003
The journal of supportive oncology
Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G +2 more
Plain English This study examined how well the drug darbepoetin alfa helps cancer patients who are anemic due to chemotherapy. Researchers found that after treatment, patients experienced an average increase in hemoglobin of 1.7 g/dL overall, and 84% of patients had a significant improvement in their hemoglobin levels. Along with better hemoglobin, patients reported feeling less fatigued, with fatigue scores improving by about 27%.
Who this helps: This benefits cancer patients undergoing chemotherapy, especially those struggling with anemia and fatigue.
Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
2002
Oncology (Williston Park, N.Y.)
Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G +2 more
Plain English This study looked at two treatments for anemia caused by chemotherapy: darbepoetin alfa given every two weeks and recombinant human erythropoietin (rHuEPO) given weekly or three times a week. Both treatments were effective, with 71% of patients seeing a significant increase in hemoglobin levels; however, fewer patients on darbepoetin alfa (7%) needed blood transfusions compared to those on rHuEPO (14%). This is important as it suggests that the less frequent darbepoetin alfa might be a better option for managing anemia in chemotherapy patients, with fewer transfusions required.
Who this helps: Patients undergoing chemotherapy.